137 related articles for article (PubMed ID: 34251183)
1. Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Deberle LM; Benešová M; Becker AE; Ratz M; Guzik P; Schibli R; Müller C
Bioconjug Chem; 2021 Aug; 32(8):1617-1628. PubMed ID: 34251183
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.
Guzik P; Benešová M; Ratz M; Monné Rodríguez JM; Deberle LM; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):972-983. PubMed ID: 33063250
[TBL] [Abstract][Full Text] [Related]
3. Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Benešová M; Guzik P; Deberle LM; Busslinger SD; Landolt T; Schibli R; Müller C
Mol Pharm; 2022 Mar; 19(3):963-973. PubMed ID: 35192367
[TBL] [Abstract][Full Text] [Related]
4. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
[TBL] [Abstract][Full Text] [Related]
5. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
6. Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate.
Müller C; Reber J; Haller S; Dorrer H; Bernhardt P; Zhernosekov K; Türler A; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):476-85. PubMed ID: 24100768
[TBL] [Abstract][Full Text] [Related]
7. Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates.
Müller C; Guzik P; Siwowska K; Cohrs S; Schmid RM; Schibli R
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914162
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo Properties.
Siwowska K; Haller S; Bortoli F; Benešová M; Groehn V; Bernhardt P; Schibli R; Müller C
Mol Pharm; 2017 Feb; 14(2):523-532. PubMed ID: 28094532
[TBL] [Abstract][Full Text] [Related]
9. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Properties of
Larenkov A; Rakhimov M; Lunyova K; Klementyeva O; Maruk A; Machulkin A
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545327
[TBL] [Abstract][Full Text] [Related]
11. Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity.
Fischer CR; Groehn V; Reber J; Schibli R; Ametamey SM; Müller C
Mol Imaging Biol; 2013 Dec; 15(6):649-54. PubMed ID: 23760583
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
[TBL] [Abstract][Full Text] [Related]
13. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.
Siwowska K; Müller C
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):269-86. PubMed ID: 26149341
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
16. Reduced
Boss SD; Müller C; Siwowska K; Büchel JI; Schmid RM; Groehn V; Schibli R; Ametamey SM
Bioconjug Chem; 2018 Apr; 29(4):1119-1130. PubMed ID: 29412638
[TBL] [Abstract][Full Text] [Related]
17. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
18. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates.
Müller C; Vlahov IR; Santhapuram HK; Leamon CP; Schibli R
Nucl Med Biol; 2011 Jul; 38(5):715-23. PubMed ID: 21718947
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]